Stock Track | Sionna Therapeutics Soars 38.89% on IPO Debut, Fueled by Strong Investor Demand

Stock Track

Feb 08, 2025

Shares of Sionna Therapeutics (SION) surged 38.89% in its trading debut on Friday, buoyed by investor enthusiasm for the clinical-stage biopharmaceutical company's successful initial public offering (IPO).

Sionna, which is developing drugs to treat cystic fibrosis, sold 10.6 million shares at $18 per share in its upsized IPO, raising $191 million. The IPO was priced at the top end of its expected range, reflecting strong investor demand for the company's shares.

Based in Waltham, Massachusetts, Sionna is vying for a share of the lucrative cystic fibrosis market, currently dominated by Vertex Pharmaceuticals. The company aims to leverage its expertise in cystic fibrosis therapeutics to develop innovative treatments for the disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1121625472"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121625472\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121625472?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-08 02:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121625472","market":"us","top_or_hot":-1,"title":"Stock Track | Sionna Therapeutics Soars 38.89% on IPO Debut, Fueled by Strong Investor Demand","media":"Stock Track","content":"<p>Shares of Sionna Therapeutics (SION) surged 38.89% in its trading debut on Friday, buoyed by investor enthusiasm for the clinical-stage biopharmaceutical company's successful initial public offering (IPO).</p>\n\n<p>Sionna, which is developing drugs to treat cystic fibrosis, sold 10.6 million shares at $18 per share in its upsized IPO, raising $191 million. The IPO was priced at the top end of its expected range, reflecting strong investor demand for the company's shares.</p>\n\n<p>Based in Waltham, Massachusetts, Sionna is vying for a share of the lucrative cystic fibrosis market, currently dominated by Vertex Pharmaceuticals. The company aims to leverage its expertise in cystic fibrosis therapeutics to develop innovative treatments for the disease.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Sionna Therapeutics Soars 38.89% on IPO Debut, Fueled by Strong Investor Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Sionna Therapeutics Soars 38.89% on IPO Debut, Fueled by Strong Investor Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-08 02:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Sionna Therapeutics (SION) surged 38.89% in its trading debut on Friday, buoyed by investor enthusiasm for the clinical-stage biopharmaceutical company's successful initial public offering (IPO).</p>\n\n<p>Sionna, which is developing drugs to treat cystic fibrosis, sold 10.6 million shares at $18 per share in its upsized IPO, raising $191 million. The IPO was priced at the top end of its expected range, reflecting strong investor demand for the company's shares.</p>\n\n<p>Based in Waltham, Massachusetts, Sionna is vying for a share of the lucrative cystic fibrosis market, currently dominated by Vertex Pharmaceuticals. The company aims to leverage its expertise in cystic fibrosis therapeutics to develop innovative treatments for the disease.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SION","symbol_name":"Sionna Therapeutics","start_time":0,"source_url":"","article_id":"1121625472","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121625472","pubTimestamp":1738951353,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Sionna Therapeutics  surged 38.89% in its trading debut on Friday, buoyed by investor enthusiasm for the clinical-stage biopharmaceutical company's successful initial public offering .Sionna, which is developing drugs to treat cystic fibrosis, sold 10.6 million shares at $18 per share in its upsized IPO, raising $191 million. The IPO was priced at the top end of its expected range, reflecting strong investor demand for the company's shares.Based in Waltham, Massachusetts, Sionna is vyi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SION":"Sionna Therapeutics"},"translate_title":"受投资者强劲需求推动，股票赛道Sionna Therapeutics首次公开募股飙升38.89%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SION":1},"content_text":"Shares of Sionna Therapeutics (SION) surged 38.89% in its trading debut on Friday, buoyed by investor enthusiasm for the clinical-stage biopharmaceutical company's successful initial public offering (IPO).\nSionna, which is developing drugs to treat cystic fibrosis, sold 10.6 million shares at $18 per share in its upsized IPO, raising $191 million. The IPO was priced at the top end of its expected range, reflecting strong investor demand for the company's shares.\nBased in Waltham, Massachusetts, Sionna is vying for a share of the lucrative cystic fibrosis market, currently dominated by Vertex Pharmaceuticals. The company aims to leverage its expertise in cystic fibrosis therapeutics to develop innovative treatments for the disease.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}